Biogen Idec Inc. (BIIB)

Check out top investors' recommendation for BIIB
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
276.67
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
67%/33%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company’s products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company’s Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Andrew Fein Chardan Capital Markets Buy   Mar 25, '19     300.00  Mar 25, '20  N/A 
Matthew Harrison UBS Sell   Mar 22, '19     210.00  Mar 22, '20  N/A 
Christopher Marai Wedbush Securities Inc. Buy   Mar 21, '19     320.00  Mar 21, '20  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Mar 04, '19     402.00  Mar 04, '20  N/A 
Alethia Young Deutsche Bank Securities Buy   Mar 04, '19     400.00  Mar 04, '20  N/A 
Andrew Fein Chardan Capital Markets Buy   Feb 04, '19     363.00  Feb 04, '20  N/A 
Matthew Harrison UBS Buy   Jan 30, '19     401.00  Jan 30, '20  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Jan 29, '19     402.00  Jan 29, '20  N/A 
Alethia Young Deutsche Bank Securities Buy   Jan 29, '19     400.00  Jan 29, '20  N/A 
Christopher Marai Wedbush Securities Inc. Buy   Oct 11, '18     420.00  Oct 11, '19  N/A 
Robyn Karnauskas Deutsche Bank Securities Buy   Oct 08, '18     470.00  Oct 08, '19  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Sep 21, '18     400.00  Sep 21, '19  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Aug 01, '18     400.00  Aug 01, '19  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Mar 16, '18     407.00  Mar 16, '19  N/A 
Alethia Young Deutsche Bank Securities Buy   Mar 12, '18     384.00  Mar 12, '19  N/A 
Adnan Butt RBC Capital Markets Buy   Mar 02, '18     400.00  Mar 02, '19  N/A 
Ian Somaiya Piper Jaffray Buy   Mar 02, '18     393.00  Mar 02, '19  N/A 
Cory Kasimov JPMorgan Buy   Feb 07, '18       Feb 07, '19  N/A 
Alethia Young Deutsche Bank Securities Buy   Feb 07, '18     384.00  Feb 07, '19  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Feb 07, '18     407.00  Feb 07, '19  N/A 
< previous123456789